Compare MDIA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDIA | IMMP |
|---|---|---|
| Founded | 2019 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.0M | 58.2M |
| IPO Year | 2019 | 2012 |
| Metric | MDIA | IMMP |
|---|---|---|
| Price | $0.83 | $0.62 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 30.4K | ★ 22.9M |
| Earning Date | 05-19-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $133,336,000.00 | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.52 | N/A |
| 52 Week Low | $0.54 | $0.29 |
| 52 Week High | $1.60 | $3.53 |
| Indicator | MDIA | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 40.17 |
| Support Level | $0.57 | $0.29 |
| Resistance Level | $0.87 | $1.89 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 81.44 | 42.48 |
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.